VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 121 filers reported holding VERVE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.25 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,085 | -13.4% | 232,620 | +22.4% | 0.03% | 0.0% |
| Q2 2023 | $3,564 | -6.2% | 190,071 | -27.9% | 0.03% | -6.5% |
| Q1 2023 | $3,801 | +191.7% | 263,620 | +291.5% | 0.03% | +63.2% |
| Q4 2022 | $1,303 | -99.9% | 67,344 | -41.0% | 0.02% | -9.5% |
| Q2 2022 | $1,744,000 | +441.6% | 114,117 | +2035.0% | 0.02% | +425.0% |
| Q2 2021 | $322,000 | – | 5,345 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,508,809 | $57,251,000 | 8.18% |
| Alphabet Inc. | 10,974,011 | $250,427,000 | 8.12% |
| M28 Capital Management LP | 178,500 | $4,073,000 | 3.74% |
| Casdin Capital, LLC | 3,138,167 | $71,613,000 | 3.21% |
| Ally Bridge Group (NY) LLC | 105,360 | $2,404,000 | 1.78% |
| Redmile Group, LLC | 1,835,328 | $41,882,000 | 1.31% |
| Cormorant Asset Management, LP | 700,710 | $15,990,000 | 1.23% |
| Novo Holdings A/S | 750,000 | $17,115,000 | 0.90% |
| Artal Group S.A. | 400,000 | $9,128,000 | 0.38% |
| PFM Health Sciences, LP | 369,765 | $8,438,000 | 0.32% |